We now share a new release including 6 years of additional follow‐up cognitive data, and additional MRI follow‐ups, clinical progression, new longitudinal behavioral and lifestyle measures (questionnaires, actigraphy), longitudinal AD plasma biomarkers, amyloid‐beta and tau positron emission tomography (PET), magnetoencephalography, as well as neuroimaging analytic measures from all MRI modalities. This evidence concerns the gene MAPT and Alzheimer disease.